Prescriptions must be reported to the database no more than one 1 business day after the date the prescription was dispensed. A report for healthcare providers e. For example: a suspicious prescriber or pharmacy that appears to be acting outside of the normal scope of practice, or an individual obtaining controlled dangerous substances CDS for any purpose other than the treatment of an existing medical condition, such as for purposes of abuse, misuse or diversion.
Access to the NJPMP is granted to prescribers, delegates and pharmacists who are licensed by the State of New Jersey and whose licensees are in good standing with their respective licensing boards.
Registered prescribers may delegate their authority to access the NJPMP to certain other healthcare professionals. Before issuing a prescription, a prescriber or the prescriber's delegate shall access prescription monitoring information for a new or current patient consistent with the following:.
If the pharmacist has a reasonable belief that the person may be seeking a controlled dangerous substance, in whole or in part, for any purpose other than the treatment of an existing medical condition, such as for purposes of misuse, abuse, or diversion, a pharmacist shall not dispense a Schedule II controlled dangerous substance, any opioid, or a benzodiazepine drug that is a Schedule III or Schedule IV controlled dangerous substance to any person without first accessing the prescription monitoring information to determine if the person has received other prescriptions that indicate misuse, abuse, or diversion.
Patient information in the NJPMP is intended to supplement an evaluation of a patient, confirm a patient's drug history, or document compliance with a therapeutic regimen.
Before accessing NJPMP data, users must certify that they are seeking information for a specific, current patient. When prescribers, their delegates, or pharmacists identify a patient as potentially having an issue of concern regarding drug use, they are encouraged to help the patient locate assistance and take any other action the prescriber or pharmacist deems appropriate.
Prescribers, delegates, and pharmacists authorized to access the NJPMP, must certify before each search that they are seeking data solely for the purpose of providing healthcare to new or current patients. Authorized users agree that they will not provide access to the NJPMP to any other individuals, including members of their staff.
The New Jersey Division of Consumer Affairs invites all members of the public to help in the fight to halt the abuse and diversion of prescription drugs. Among these drugs are Xanax and Valium, tranquilizers commonly prescribed to humans and also used to treat separation anxiety and thunderstorm phobias in dogs; hydrocodone, a potent opioid used to relieve pain and suppress coughs in pets and people; and tramadol, a powerful painkiller often prescribed for humans and animals with arthritis or other debilitating ailments.
By creating stricter standards for the way pet prescriptions are written, filled, and entered into the NJPMP, the database will become a more valuable tool for veterinarians and other prescribers to identify signs of possible medical diversion by pet owners. This month, the Board of Veterinary Medical Examiners has sent letters to its 2, members, recommending that they record the following information on each prescription provided to owners to treat their animals:.
The Board of Pharmacy previously sent letters to its16, members recommending that they place the same information on prescription labels and record it in the NJPMP. Information contained in the reports will be investigated for possible administrative or criminal enforcement action.
Physicians, dentists, podiatrists, optometrists, advance practice nurses, and certified nurse midwives who are authorized by the State of New Jersey to prescribe or dispense CDS are required to check the NJPMP the first time they prescribe a Schedule II CDS to a new or current patient for acute or chronic pain, and on a quarterly basis every three months during the period of time a current patient continues to receive a prescription for a Schedule II CDS for acute or chronic pain.
PDF , with the goal of tracking and controlling the volume of prescription-dispensed drugs subject to abuse. This database is updated daily and grants access to New Jersey-licensed prescribers and pharmacists who are in good standing with their respective boards. The NJPMP is also used to mitigate the risk of potential abuse or fraud by individuals who obtain prescriptions from multiple providers.
NJPMP dca. Jeffrey D. Laszczyk, Jr. Box Newark, New Jersey New Jersey Department of Health. New Jersey State Commission of Investigation. Partnership for a Drug-Free New Jersey. Reach NJ. Another group or vendor provides the info on the next page. It has info for health care providers. Aetna Better Health provides the general info on the next page.
0コメント